Creative Medical Technology Holdings (CELZ) EBIT Margin (2017 - 2025)
Creative Medical Technology Holdings' (CELZ) quarterly EBIT Margin came in at 64859.4% in Q4 2025, down 200160.0% year-over-year from N/an in Q4 2024, and down 17.18% quarter-over-quarter from 55349.27% in Q1 2025.
Powered by 
Analysis
Creative Medical Technology Holdings (CELZ) EBIT Margin (2017 - 2025) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported EBIT Margin for 9 consecutive years, with 64859.4% the latest figure, recorded in Q4 2025.
- On a quarterly basis, EBIT Margin fell 200160.0% year-over-year to 64859.4% in Q4 2025; TTM through Jun 2026 was 208004.4%, a 10934763.0% decrease from a year earlier, with the FY2025 full-year figure at 102380.23%, down 5016332.0% from the prior year.
- EBIT Margin was 64859.4% for Q4 2025 at Creative Medical Technology Holdings, down from 55349.27% in the prior quarter.
- Over five years, EBIT Margin peaked at 1855.31% in Q3 2022 and troughed at 64859.4% in Q4 2025.
- A 5-year average of 28928.09% and a median of 23018.04% in 2024 frame the typical range for EBIT Margin.
- The widest YoY moves for EBIT Margin: up 647905 bps in 2022, down 3157871 bps in 2022.
- Over 5 years, EBIT Margin stood at 2173.64% in 2021, then tumbled by 1453 bps to 33752.35% in 2022, then plunged by 75 bps to 59061.3% in 2023, then retreated by 6 bps to 62857.8% in 2024, then fell by 3 bps to 64859.4% in 2025.
- The last three EBIT Margin figures came in at 64859.4% (Q4 2025), 55349.27% (Q1 2025), and 62857.8% (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | -25,827.14% |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 0.56% |
| 10 | Creative Medical Technology Holdings | 1.48 Mn | 1.50 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -64,859.40% |
| Mar 31, 2025 | -55,349.27% |
| Dec 31, 2024 | -62,857.80% |
| Jun 30, 2024 | -20,316.33% |
| Dec 31, 2023 | -59,061.30% |
| Sep 30, 2023 | -25,719.75% |
| Dec 31, 2022 | -33,752.35% |
| Sep 30, 2022 | -1,855.31% |
| Mar 31, 2022 | -7,699.13% |
| Dec 31, 2021 | -2,173.64% |
| Sep 30, 2021 | -8,334.36% |
| Jun 30, 2021 | -5,158.42% |
| Dec 31, 2020 | -1,846.08% |
| Sep 30, 2020 | -314.90% |
| Jun 30, 2020 | -767.97% |
| Mar 31, 2020 | -795.81% |
| Dec 31, 2019 | 7,513.39% |
| Sep 30, 2019 | -475.52% |
| Jun 30, 2019 | -447.17% |
| Mar 31, 2019 | -493.50% |